ANDEMBRY

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 21 Jan 2026 filing date already counts against anyone who files later.

Record

Serial number

99605949

Mark type

Design + words

Filed

21 Jan 2026

Published for opposition

21 Apr 2026

Attorney of record

Scott Woldow

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE

Owner

• CSL Behring GmbH, Marburg, DE

Prosecution history

• 24 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 24 Mar 2026 — EXAMINER'S AMENDMENT ENTERED
• 24 Mar 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 24 Mar 2026 — EXAMINERS AMENDMENT E-MAILED
• 24 Mar 2026 — EXAMINERS AMENDMENT -WRITTEN
• 23 Mar 2026 — ASSIGNED TO EXAMINER
• 23 Mar 2026 — NOTICE OF DESIGN SEARCH CODE E-MAILED
• 23 Mar 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 21 Jan 2026 — APPLICATION FILING RECEIPT MAILED
• 21 Jan 2026 — NEW APPLICATION ENTERED